that's also apart from the fact that the FDA would have approved the patient levels, they do tend to set them,
AND as I've foreshadowed many times, the FDA is lightening up on stem cell clinical trials. See?
madamswer was aghast at the unlikelihood of this ever happening, but it's clearly the case!
So instead madamswer is attempting to suggest that patient levels are lower at the cost saving discretion of MSB, and would be because they are worried about the commitment of Teva?
How utterly improbable!!
(I drafted a reply taking apart madamswer's last efforts at obfuscation, and addressing the absurd claims of vindictiveness a few posts ago, but best leave the facts speak for themselves).
Timeframe for 2015, page-49
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.31 |
Change
0.150(13.0%) |
Mkt cap ! $1.490B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.33 | $1.15 | $25.26M | 19.99M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 161000 | $1.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.31 | 50400 | 2 |
View Market Depth
| Last trade - 16.10pm 23/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |